Skip to content
Search

Latest Stories

New Johnson & Johnson drug authorised in Britain for schizophrenia treatment

In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized a new Johnson & Johnson drug in Britain.

Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to six months of symptom control and a reduction in their risk of relapse with only two doses a year.


It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous absorption of paliperidone palmitate over a six-month period.

“Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication,” said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.

“Long-acting injectable treatments can offer better protection against relapse and greater patient convenience compared with oral medication.”

According to Johnson & Johnson, the MHRA authorization is based on data from its randomized, double-blind, non-inferiority Phase 3 global study designed to demonstrate that PP6M is not less effective than PP3M for the prevention of relapse in participants previously stabilized on a shorter-acting formulation of paliperidone palmitate.

The results showed non-inferiority of PP6M compared with PP3M on the primary endpoint of time to first relapse at the end of the 12-month period. Results found that 91.9 percent of patients treated with PP6M and 94.8 percent treated with PP3M were relapse-free at 12 months.

“The MHRA authorization for PP6M marks a significant step in providing a new therapeutic solution for people with schizophrenia that will help them feel less defined by their medication,” said Vinay Patroe, Medical Affairs director, Janssen UK.

“At Janssen, we are focused on preventing relapse and improving real world outcomes for people living with schizophrenia, and this approval is a key milestone in our ongoing work to help change the paradigm in treating schizophrenia with long-acting treatments.”

Schizophrenia is a chronic and severe brain disorder affecting nearly 300,000 people in the UK.

More For You

Pharmacy owners to receive 19p SAF increase in advance payments for April and May 2025

The Single Activity Fee (SAF) was increased by 19p to £1.46 per item, effective from April 2024.

gettyimages

19p SAF increase to be included in April and May 2025 advance payments

Following discussions with the Department of Health and Social Care (DHSC), Community Pharmacy England (CPE) has agreed a mechanism that will allow pharmacy owners to receive the 19p increase to the Single Activity Fee (SAF) earlier for the dispensing months of April and May 2025.

CPE said: “The advance payments for these dispensing months will be adjusted to incorporate the uplift to the SAF. No adjustment to advance payments will be required from the June 2025 dispensing month onwards.”

Keep ReadingShow less
CPE invites pharmacy owners to share their views on new CPCF funding settlement

What do you think should be the next priority for the Government?

gettyimages

Pharmacy owners asked to share their views on new CPCF arrangements

Community Pharmacy England (CPE) is urging pharmacy owners to share their views on the new Community Pharmacy Contractual Framework (CPCF) funding settlement ahead of its next full Committee meeting, scheduled for 30 April–1 May.

The Committee said it had agreed to the settlement "reluctantly," acknowledging that it represents a significant shift after years of real-terms funding cuts, while admitting that it’s “still not sufficient to match the continued scale of pressures facing pharmacy businesses.”

Keep ReadingShow less
Homecare medicines services face many challenges beyond pharmacy's control

Homecare medicines services face many challenges beyond pharmacy's control

gettyimages

GPhC calls for industry-wide collaboration to strengthen homecare medicines services

The General Pharmaceutical Council (GPhC) has called for industry-wide collaboration to improve homecare medicines services to ensure patients always receive their medicines when needed.

The call follows a recent review by the regulator, which identified several challenges facing homecare services, many of which were beyond the immediate control of the pharmacies providing them.

Keep ReadingShow less
Lack of funding deters NI pharmacy contractors from expanding portfolio

W G Hamilton Pharmacy is the third pharmacy in Northern Ireland to be recently sold to first-time buyers.

Pharmacy ownership trends shift in Northern Ireland due to funding gap

An increasing number of pharmacies in Northern Ireland are being acquired by first-time buyers, as existing contractors and groups pull back from expanding their portfolios amid ongoing funding pressures, according to specialist business property adviser Christie & Co.

Among the most recent sales is W G Hamilton Pharmacy, a busy community pharmacy in Ballysillan, North Belfast.

Keep ReadingShow less
RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less